Stereotactic Magnetic Resonance Guided Radiation Therapy
NCT04115254
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Pancreas Cancer
- Lung Cancer
- Renal Cancer
- Adrenal Metastases
- Prostate Cancer
- Liver Metastases
- Oligoprogressive Nodal Metastases
- Metachronous Nodal Metastases
- Synchronous Nodal Metastases
- Mesothelioma
- Spine Metastases
- Brain Metastases
- Borderline Resectable Pancreatic Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Dana-Farber Cancer Institute
- Last updated on ClinicalTrials.gov
- November 13, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 2
- Brigham & Women's Hospital · Boston, MA
- Dana Farber Cancer Institute · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.